Spero Therapeutics LLC
Enfeebling Pseudomonas with a chemical inhibitor of transcription
This article was originally published in Start Up
Spero Therapeutics LLC was formed to develop antibiotics based on a novel mechanism, to treat infections with high unmet need. Its lead program, initiated in 2013, commercializes the research of Laurence Rahme of Mass General, who invented a method for using small molecules to inhibit MvfR, a transcription regulator utilized by gram-negative bacteria including Escherichia coli, Pseudomonas aeruginosa, and Klebsiella.
You may also be interested in...
The firm is developing a novel class of antibacterials that could enable shelved agents for Gram-positive infections to reach and kill Gram-negative bacteria.
The number of deals signed by biopharma start-ups increased 7% in 2014, which featured a bump in partnerships for infectious disease drugs and multiple option-to-acquire agreements.
Roche gets an option to acquire program addressing drug-resistant gram-negative infections when it reaches IND-filing status. Spero is working on a novel target found originally in infected tobacco plants.